$BCRX PT 23 and higher (fm @Snake Doc)BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BCRX trade ideas
$BCRXEntry price: 8.27
Fundamentals:
- Sector: Medical - Biotech
- EPS % Chg (Last Qtr): 24%
- EPS % Chg (Previous Qtr): 24%%
- 3 Year EPS Growth Rate: 0%
- EPS Est % Chg (Current Yr): 0%
- Sales % Chg (Last Qtr): 243%
- Sales % Chg (Previous Qtr): 98%
- 3-Year Sales Growth Rate: 25%
- Annual Pre -Tax Margin: -223%
BCRX - keep trading the pullbackNote from BoA Global Research: "BCRX announced a royalty purchase agreement with RPRX and a credit loan agreement with Athyrium. BCRX will receive an upfront $125mn cash from RPRX, in exchange for 8.75% sales-based royalties up to $350mn annual sales, 2.75% royalties between $350mn-$550mn and tiered revenues outside of key territories for the recently-approved Orladeyo in preventing hereditary angioedema (HAE) attacks. The agreement also grants RPRX 1% sales royalty on its oral Factor D inhibitor BCX9930 that’s currently being evaluated in treating paroxysmal nocturnal hemoglobinuria (PNH). BCRX will also draw $125mn from the $200mn credit facility with Athyrium to repay outstanding ~$44mn debt with MidCap Fin. Trust and support its ongoing launch of Orladeyo and R&D development. We positively view today’s updates, as the agreements strengthen the company’s balance sheet and remove the near term need for dilutive financing. It also extends its cash runway meaningfully and allows the company to focus on advancing the early-stage BCX9930 program."
$BCRX BioCryst Pharmaceuticals, Gap fill Trade to $7.20 BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
BCRX potential big moveMultiple bullish indicators across all time horizons. Exiting cup and handle with bullish trends and CS patterns. Support between 4.9-5. First target 5.82 followed by potential short opportunity as it tests support at 5. Following previous year's market structure and price action, backed by upcoming announcements regarding product release and test results, long target 16+.
Keep an eye on RSI and 8 hour EMA/MA cross as price action historically respects both pretty strictly. Dragonfly Doji's also a strong indicator for big moves.
*This is a personal idea and not a recommendation
BioCryst Pharna is going to search lower for support ($3.25?)Broke under the 20dma, and I think this has further to fall. The Short Float being this high with this much institutional activity has me thinking a big fish is dragging this down. Will be important to watch the float disappear which could really move this thing. Till then I think it is a short.